focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.34
Bid: 2.21
Ask: 2.36
Change: 0.045 (1.96%)
Spread: 0.15 (6.787%)
Open: 2.35
High: 2.37
Low: 2.33
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: RA International loss narrows as revenue grows

Thu, 07th Sep 2023 17:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Pantheon Resources PLC - London-based oil and gas company focused on onshore operations in the US - Agrees a private placement of 11.9 million shares at a price of GBP0.1878 each for a total USD2.8 million to IPGL Ltd, a long-term shareholder. Pantheon will use the funds to pay the full quarterly bond repayment of the same amount. Therefore, the placement is cash-neutral and should result in materially similar dilution than would have been the case had the company settled the bond repayment in shares.

----------

Immupharma PLC - London-based drug discovery and development company - Further to announcement on August 31, raises GBP130,683 via the issue of around 6.5 million shares at 2 pence each to existing retail investors, in addition to the GBP1.4 million raised in the subscription and direct subscription. Notes Lisa Baderoon, director, subscribed for 1.0 million retail offer shares.

----------

Technology Minerals PLC - London-based battery metals mining and recycling firm - Raises GBP700,000 from a long-term shareholder through the issue of convertible loan notes. The convertible loan notes carry a coupon of 12% for a term of twelve months from issue and are convertible into shares at 1.4 pence each. "The funding will support the company as it continues to advance its exploration assets up the value curve and Recyclus progresses through the commissioning phase at its Li-ion battery recycling plant and moves closer to commercial production," says Alex Stanbury chief executive.

----------

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces further progress from Hikma in the development of ready-to-use injectable medicine AT307, following a recent positive pre-investigational new drug application meeting between Hikma and the US Food & Drug Administration. In January, Arecor transferred all rights and responsibility for future development and commercialisation of AT307 to Hikma as part of an earlier co-development and license agreement. Under this pact, Arecor is eligible to receive development milestone payments in addition to future recurring revenue from royalty payments upon commercialisation. Hikma has communicated to Arecor its intention to continue the development of AT307 in the US using the FDA's 505(b)(2) regulatory pathway. This pathway provides companies with an abbreviated regulatory review process when evidence of safety and clinical efficacy generated for an originator product is deemed suitable to be relied upon in new marketing applications.

----------

Egdon Resources PLC - Reading-based oil and gas explorer and producer - Further to the announcement of August 7, says Egdon, York Energy (UK) Holdings Ltd and Cuadrilla North Cleveland Ltd have executed a fully termed agreement to enable a farm-in and equalisation of interests between the PL81 and PEDL347 licences. Licences will be assigned as follows: Egdon 52.5%, Cuadrilla 25% and York 22.5%. Egdon would be appointed as the operator of the licences. As consideration, Egdon will pay 100% of the costs associated with the planning, drilling, logging, and either short term testing and completion or plugging and abandonment of a well to optimally test the Weaverthorpe prospect.

----------

Canadian General Investments Ltd - closed-end equity fund focused on Canadian firms - Reports net asset value per share at August 31 was USD57.57, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 20.9% and 21.6%, respectively. No comparative NAV figure was given.

----------

RA International Group PLC - specialist provider of complex and integrated remote site services - Says in the six months to June 30 revenue rose 4.1% to USD30.4 million from USD29.2 million the year prior. Pretax loss narrowed to USD2.5 million from USD3.4 million with loss per share of 1.4 pence compared to 2.0p the year before. Highlights order book of USD 71 million at June 30, although this was down from USD96 million last year.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
14 Mar 2019 10:41

ImmuPharma Preparing For Lupuzor Drug Managed Access Programme

LONDON (Alliance News) - ImmuPharma PLC said it is in final preparations to open a managed access programme for its lupus drug Lupuzor to patients in Europe.Shares in the drug discovery and

Read more
26 Feb 2019 12:06

ImmuPharma upbeat on product from subsidiary Ureka

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.

Read more
31 Dec 2018 12:00

ImmuPharma and Incanthera extend exclusivity period for Nucant agreement

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.

Read more
7 Dec 2018 11:26

ImmuPharma Progressing To Make Lupuzor Available To Patients

LONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access drug said

Read more
7 Dec 2018 08:09

Immupharma plots patient recruitment for Lupzor trials

(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.

Read more
26 Sep 2018 13:55

ImmuPharma still banking on Lupuzor even after failed trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.

Read more
26 Sep 2018 12:53

Wednesday broker round-up

(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.

Read more
26 Sep 2018 12:40

ImmuPharma Interim Loss Widens On Higher Costs And Lower Revenue

LONDON (Alliance News) - ImmuPharma PLC said on Wednesday it continues to progress its lupus treatment Lupuzor, as it saw a widened loss for the first half of 2018 due to higher costs and lower a

Read more
9 Sep 2018 10:59

Sunday share tips: Immupharma, PCF Bank

(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.

Read more
7 Sep 2018 11:43

ImmuPharma Inks Pact With Incanthera For Nucant Cancer Programme

LONDON (Alliance News) - ImmuPharma PLC said Friday it signed a clinical development collaboration for the Nucant cancer programme with Incanthera Ltd, a specialist oncology development the terms

Read more
7 Sep 2018 08:10

Immupharma to make 'blockbuster' lupus treatment available

(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.

Read more
14 Jun 2018 12:02

Immupharma Says P140 Peptide Shows Positive Results In CIDP Treatment

LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating were trading

Read more
29 May 2018 09:40

ImmuPharma Excited Despite Widened Loss As Lupuzor Makes Good Results

LONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug development company reported a a

Read more
23 Mar 2018 11:17

ImmuPharma Prepares To Report Lupuzor Study Results In April

LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III

Read more
25 Jan 2017 14:33

ImmuPharma trial of Lupuzor continuing smoothly

(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.